Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use

HIV Infections Clinical Trial

— ALCTXT  

Official title:

Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02603471
• Other study ID #: ALCTEXT
• Status: Completed
• Phase: N/A
• Start date: July 2014
• Est. completion date: December 2016

Study information

• Verified date: April 2022
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study, for HIV positive alcohol dependent adults currently taking naltrexone, is a pilot randomized controlled trial (RCT) examining the outcomes of a 12-week behavioral support program delivered via text-messaging.

It is expected that the text messaging intervention will reduce alcohol use and HIV-risk behaviors. The investigators also hypothesize that the intervention will improve adherence to HIV treatment and naltrexone.

To test the effects of the intervention on these target outcomes, 25 participants receiving the text messaging intervention will be compared to 25 participants receiving an informational pamphlet. The pamphlet will contain information about the importance of HIV treatment adherence, reducing HIV risk behaviors, and health consequences associated with alcohol use.

By providing support to maximize HIV treatment regimen and naltrexone adherence, coupled with coping skills to promote abstinence from alcohol, the text messaging intervention may provide a promising, cost-effective, and easily deployable behavioral support program for alcohol users who are HIV-infected.

Description:

The aims of this study are to: 1) implement and evaluate a 12-week cognitive behavioral therapy (CBT) intervention using text messaging via mobile phone technology (ALC-TXT-CBT) to reduce alcohol use, reduce HIV-risk behaviors and facilitate medication adherence in a population of alcohol dependent adults with HIV-infection and 2) examine potential mechanisms of action of ALC-TXT-CBT. The investigators hypothesize that ALC-TXT-CBT will produce greater reductions in alcohol use and HIV-risk behaviors, and will improve HIV treatment regimen and naltrexone (Vivitrol) adherence, relative to the control condition (informational pamphlet).

Further, the investigators expect that ALC-TXT-CBT will facilitate greater changes in negative affect, self-efficacy, and social support, and these changes will be associated with substance use outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 or older;

2. DSM-IV diagnosis of Alcohol Dependence;

3. Use of 5 or more standard drinks per drinking day for men or 4 or more for women (over the past 30 days);

4. HIV-infected serostatus;

5. Able to provide informed consent;

6. Willing and able to participate in study procedures,

7. Good general health or, in the case of a medical/psychiatric condition needing ongoing treatment, potential participant should be under the care of a physician who provides documented willingness to continue participant's medical management and coordinate care with the study physicians.

8. Adherent to <90% of antiretroviral therapy regimen, as determined by the medication adherence screening procedure

9. Currently taking or interested in taking/receiving more information about naltrexone in its injectable form (Vivitrol). Participants WILL NOT be prescribed or given naltrexone as part of this study. Participants not currently on vivitrol will be referred to a physician in the community to be evaluated for vivitrol eligibility and to receive vivitrol if applicable.

10. Owning a cell phone. Participants are required to own their phone and cannot use someone else's phone.

Exclusion Criteria:

1. Presence of serious medical condition that would, in the opinion of the study physician, make participation medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease).

2. A current pattern of alcohol or sedative use, as assessed by the study physician, which would preclude safe participation in the study and/or would likely require imminent medical detoxification.

3. Has undergone more than one inpatient medical detoxification treatment;

4. Lack of proficiency in English;

5. Currently homeless (unless residing in a recovery home for which contact information can be provided);

6. Presence of clinically significant psychiatric symptoms as assessed by MINI, such as psychosis, acute mania, or suicide risk that would require immediate treatment or make study compliance difficult.

7. Not currently taking naltrexone in its injectable form (Vivitrol) or not interested in taking/receiving information about vivitrol or not interested in taking vivitrol

8. Adherent to > or =90% of antiretroviral therapy regimen, as determined by the medication adherence screening procedure.

Related Conditions & MeSH terms

• Alcohol Dependence
• Alcoholism
• HIV Infections

Intervention

Other:
• Informational group
A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.

Behavioral:
• Text Messaging CBT (TXT-CBT)
Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.

Locations

Country	Name	City	State
United States	UCLA Integrated Substance Abuse Programs	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change Outcome Measure: Substance Use (ASI)	Addiction Severity Index (ASI) is an instrument widely used in addiction research to quantify drug use frequency and related problem areas.	baseline (week 0), treatment-end (week 12), and Follow-Up (FU) (week 24)
Primary	Change Outcome Measure: HIV Risk (RBRA)	Risk Behavior Survey (RBRA): The RBRA is a brief interview assessing involvement in HIV risk behaviors in the areas of drug use and sex in the previous 30 days. Additional items include whether the sexual partner uses or injects drugs. The participants' change in RBRA scores is being assessed from each timepoint to the next.	RBRA will be collected at baseline (week 0), treatment-end (week 12), and FU (week 24)
Primary	Change Outcome Measure: Adherence Measures	ART Adherence. The investigator will use monthly phone-based unannounced pill counts (UPCs).	Baseline, Weeks 4,8,12,16,20 and 24
Primary	Change Outcome Measure: Substance Use (UDS)	Urine Drug Screen (UDS). Urine drug screens will be collected monthly using temperature controlled test cups. An FDA-approved one-step test will be used. During the 12-week treatment period, one full-screen panel and two panels only testing for opioids (heroin and prescription opioids) will be conducted. The UDS will test for the presence of: amphetamines, benzodiazepines, methadone, cocaine, methamphetamine, morphine (heroin), hydrocodone (Vicodin), oxycodone (OxyContin), and marijuana. The participants' change in substance use over time (as assessed by the ASI and UDS results) is being assessed from each timepoint to the next.	UDS is collected at baseline, week 4, week 8, week 12 and week 24
Primary	Change Outcome Measure: Viral Load	Viral load will serve as a biological indicator of adherence. Consistent with the typical frequency with which viral load is assessed in clinical settings, data concerning viral load will be collected at baseline (week 0), treatment end (week 12), and FU (week 24) via chart review from the participant's medical provider.	at baseline (week 0), treatment end (week 12), and FU (week 24).
Secondary	Change in Quality of Life	Data concerning health-related quality of life during and after treatment will be collected using the SF-12 Health Survey. It measures eight health domains, and each survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.	Weeks 0,12 and 24